Scientists test new cancer Drug's safety in men with liver issues
NCT ID NCT06860243
Summary
This study looked at how a new prostate cancer drug, opevesostat, is processed by the body in men with moderate liver problems compared to healthy men. Researchers gave a single dose to 16 participants and measured drug levels in their blood over time to understand if liver impairment changes how the drug works. The goal was to gather safety information to guide future dosing for patients with liver conditions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Pharmacology of Miami ( Site 0002)
Miami, Florida, 33172, United States
-
Texas Liver Institute ( Site 0001)
San Antonio, Texas, 78215, United States
Conditions
Explore the condition pages connected to this study.